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Pancreatic cancer is one of the common digestive system cancers, and its preferred treatment is still surgery. However, because of its hidden onset and nonspecific early clinical symptoms, advanced disease or distant metastasis often exists at the time of diagnosis. Therefore, only 5% to 15% of pancreatic cancer has the opportunity of radical resection, with a postoperative median survival time ranging from 6 to 12 months [1] ; and because local tumor is easy to recur, the average survival time is only 5 to 7 months after palliative surgery. Since 90% of pancreatic cancers are adenocarcinoma, which has poor radiosensitivity, and the tolerance doses of surrounding critical organs such as liver, stomach, small intestine, kidney, and spinal cord are low, the dose of conventional radiation therapy is difficult to raise, and it is difficult to implement radical radiotherapy. Intraoperative radiotherapy and interstitial brachytherapy, which have been carried out since 1970s, can improve tumor dose and reduce the dose of normal tissues and organs, but the implementation process is complex and difficult to be conducted widely.
Since 1980s, with the development of radiation physics, imaging, and computer technology, precise treatments such as stereotactic radiation therapy and threedimensional conformal radiation therapy get more and more attention [2] . Stereotactic conformal radiotherapy is a stereotactic isocenter noncoplanar fractionated irradiation technology www.cjcsysu.cn with precise computed tomography (CT) location. It can focus radiation on the tumor target accurately, and then improve the tumor dose, while the surrounding normal tissues only receive relatively small doses of radiation that can be tolerated. Therefore higher therapeutic ratio and better biological effect are obtained due to its bigger single dose compared with that of conventional treatment, and gratifying efficacy has been made in clinical application. Yu . [3] reported the results of stereotactic radiotherapy for advanced pancreatic cancer, and the 1 and 2year survival rates were 92.3% and 70.0% , respectively. Zhou .
[4]
reported the 1 and 2year survival rates were 81.2% and 26.0%, respectively. Although these results are encouraging, the stereotactic radiotherapy used clinically is based on common linear accelerator, and in the process of treatment, since breathing movement can lead to tumor location uncertainty, patients should be strictly immobilized. If radiation volume is increased to wrap all target volume, the planning target volume (PTV) increases more significantly than does the clinical target volume (CTV), which increases the normal tissue volume irradiated by high dose and limits dose escalation. To resolve the impact of respiratory movement, passive methods such as respiratory gating technique, active breathing control technique, and deep inspiration breathhold technique are clinically used, but these methods are difficult to be widely applied in the clinical treatment of pancreatic cancer. Recently, fourdimensional CTbased radiotherapy has been preliminarily carried out clinically, whose theoretical premise is that the movements of target tumor and surrounding organs at risk are identical to their respective movements at image positioning. This premise can only be established approximately, because human respiratory motion is not strictly repetitive, and when large fraction technologies (such as stereotactic radiotherapy) or complex technologies (such as intensity modulated radiation therapy) are used, human body will have involuntary movement and be difficult to maintain immobilized position, so it is not a realtime tracking. For those previously undetermined movements, realtime tracking treatment technology is the best technology to ensure accuracy.
As a new means of radiotherapy, CyberKnife can avoid the error caused by respiratory movement through synchronous respiratory tracking technology (Synchrony) by implanting fiducials in tumor and XSight spine tracking technology (XSight), and can truly track tumor movement synchronizing with respiratory, giving a higher dose to tumor more accurately while reducing the dose of normal tissues [5, 6] . At the same time, because of the high conformal degree of tumor target in CyberKnife treatment, the PTV as well as the volume of normal intestine and stomach irradiated by high dose are significantly reduced, and then the dose to gastrointestinal tract decreases significantly, with lower incidence of nausea and vomiting. CyberKnife treatment was introduced into our hospital in March 2009, and here the CyberKnife treatment process and preliminary clinical efficacy of 20 patients with advanced pancreatic cancer were analyzed to understand the treatment principle and characteristics of CyberKnife treatment system, and to further improve the efficacy of CyberKnife treatment for locally advanced pancreatic cancer.
Between April 2009 and February 2010, 20 patients with advanced pancreatic cancer were treated at Radiotherapy Center, Nanjing General Hospital of Nanjing Military Region. All patients refused surgery or had no surgical indications. Among 20 patients there were 14 males and 6 females, whose age ranged from 42 to 78 years, with a mean age of 56 years and a median age of 54 years. There were 13 patients with pancreatic head cancer and 7 patients with pancreatic body and tail carcinoma, with KPS score ranging from 70 to 90 points. Fourteen patients had abdominal back pain and 7 had jaundice. Sixteen patients were diagnosed by pathology and 4 patients were diagnosed by typical clinical manifestations and positron emission tomography (PET)CT imaging. According to the 2003 International Union Against Cancer (UICC) clinical staging system, 7 patients had stageII and 13 patients had stageIII diseases (Table 1) .
Patients were in supine position with the body immobilized by a vacuum pad. Spiral CT scanning was conducted with a slice thickness of 1 mm, and scanning covered the whole pancreas and regions of 15 cm up and down of the lesions. CTV was defined as the region of 1 to 2 mm outside the gross tumor volume (GTV) in , , and axes covering the small subclinical lesions. With XSight tracking technology, before target delineation, the motion ranges of pancreatic lesion in three dimensions were observed under the simulator when patients had quiet breathing, and then the scope of PTV was extended to 23 mm outside CTV. Among 20 patients the tumor PTV ranged from 26 to 64 cm 3 with a median value of 47 cm 3 . Prescription dose was defined as 95% of the dose of PTV.
All 20 patients were treated by CyberKnife SRS system (Accuray, USA) alone. Vertebral tracking (XSight) treatment technology was used for 5 patients. When positioning, according to the relationship between the locations of reference vertebral body and digital reconstructed image based on CT scanning, the correct reference position was found by bed automatically moving, and then treatment began. In 15 patients treated with respiration synchronous tracking technique (Synchrony), at least one gold seed fiducial was required to be implanted within or around the tumor through CTguided 19G needle, and within 2 h after implantation CT scan was performed to observe whether the gold seed fiducial was in proper position; at 7 to 10 days after implantation CT scan was performed again, and at this time local hemorrhage and edema existed around the gold seed fiducial, while the gold seed fiducial was relatively stable and no longer moved.
When the CyberKnife treatment plan was designed [7] , the single point maximum dose was used as the limit standard for 野series冶 organs, and the single maximum dose of part volume was used as the limit standard for 野parallel冶 organs. Five fractions were used as the limit standard for single point dose. Since only two patients had more than 5 fractions, the limit standard for single dose was appropriately increased for those patients with 6 fractions. The actual received doses and limit standards of normal tissues are shown in Table 2 . Conformality Index (CI, the ratio of tissue volume to tumor volume wrapped by prescription isodose line) and New Conformality Index (nCI: CI 伊 tumor volume/ tumor volume wrapped by prescription isodose line) were used for the assessment of treatment plan.
Before treatment, respiratory monitoring device was used to continuously detect the position of the infrared generator placed on the patient chest to create dynamic respiratory rhythm, and Xray digital imaging of kV level was collected at different time points of respiratory rhythm to obtain the dynamics model between gold seed fiducial (tumor) position and respiratory rhythm, and then the respiratory model was used to guide accelerator to track the lesions within the pancreas and give dynamic radiation. The prescription dose of lesions was 32 to 55 Gy (median dose Abbreviation: CI, conformality index. The conformality index is the ratio of the tissue volume receiving the prescription isodose or more to the tumor volume receiving the prescription isodose or more. nCI: new conformality index. The new conformality is the CI multiplied by the ratio of the total tumor volume to the tumor volume receiving the prescription isodose or more.
treatment plan of a patient with stageIIB disease (the prescription dose of 82% isodose level was 48 Gy/6 fractions, PTV was 42 cm 3 , and the lesion nCI was 1.26).
Among 15 patients treated by simultaneous respiratory tracking technology (Synchrony), 1 patient developed severe abdominal pain (puncturerelated intestinal bleeding), and after intervention therapy the bleeding was stopped and treatment was successfully completed; 5 patients had mild nausea and 3 patients had moderate nausea and vomiting, and, after active dehydration and antiemetic treatment, the symptoms improved. The remaining patients had the main complaint of local mild pain at the puncture point, and had no significant nausea or vomiting. The 5 patients treated by XSight technology could well tolerate CyberKnife treatment even with poor health, among whom 2 patients complained of mild fatigue and nausea, 2 patients had moderate nausea and vomiting, which improved after symptomatic treatment, and 1 had no obvious symptoms, as shown in Table 4 .
Abdominal CT was regularly conducted to evaluate 45 Gy), the fraction number was 3 to 6 (median 4), once per day (rest on Saturdays and Sundays), and the total treatment time was 3 to 8 days (median 4 days). The equivalent biological dose was 80 to 120 Gy when 琢 / 茁 value was equal to 10. During the treatment, antiemetic, dehydration, improving appetite, and other appropriate symptomatic treatments were given when complications such as nausea, vomiting, fatigue, and anorexia occurred.
Upper abdominal CT scanning was performed at 6 to 8 weeks after treatment. The Response Evalution Criteria in Solid Tumors (RECIST) was used to evaluate treatment efficacy, and the Radiation Therapy Oncology Group (RTOG) radiation injury grading criterion was used to evaluate radiation injury. Followup was performed every 3 months to a total of 3 to 11 months, with a median followup of 7 months. SPSS13.0 statistical software was applied for data analyses. Chisquare test was used to compare the groups爷 indicators of preliminary clinical results (tumor markers, jaundice index and so on), and a value less than 0.05 was considered statistically significant.
The isodose level of prescription dose in treatment plan was 75% to 85% , with a median value of 79% . Radiation fields were 150 to 200 noncoplanar fields. The treatment plan showed that the mean CI of pancreatic lesions in all patients was 1.12, and the mean nCI was 1.28, as shown in Table 3 . Figure 1 showed Critical structure Figure 1 The dosimetry index of one patient with stage鄄 IIB pancreatic cancer during CyberKnife radiosurgery treatment shortterm efficacy, and the results showed that 6 patients had complete remission, 9 had partial remission, 3 had stable disease, 1 had progression, and 1 died. Figure 2 showed the changes of CT scan 3 months after treatment in a patient with stageIIB disease. At 3 to 11 months after treatment, 19 patients survived and 1 patient had cancerrelated death. The dead patient had liver, lung, and bone metastasis and developed cachexia before death.
The 15 patients with pain were assessed by pain visual scoring method. Before treatment 2 patients had 9 scores, 4 had 8 scores, 3 had 7 scores, 1 had 6 scores, 4 had 5 scores, and 1 had 4 scores. These patients all took different doses of strong opioid analgesics. After treatment, 1 patient with 8 scores and 1 with 7 scores changed to take weak opioid analgesics; other patients had complete pain relief and stopped taking analgesics. The pain relief rate was nearly 90%.
Before treatment, the mean value of CA199 in 20 patients was 287 IU/mL (18587 IU/mL), whereas within 2 months after CyberKnife treatment the mean value was 45 IU/mL (795 IU/mL), with significant difference ( < 0.05).
Of 13 patients with obstructive jaundice, 10 had obviously relieved jaundice after treatment, with a remission rate of 76.9% . Before treatment, the mean values of total bilirubin and combined bilirubin were 114 滋 mol/L (45354 滋 mol/L) and 24 滋 mol/L (8103 滋 mol/L), whereas after treatment the mean values were 15 滋 mol/L (342 滋 mol/L) and 4 滋 mol/L (214 滋 mol/L) respectively, with significant difference ( < 0.05).
In 20 patients after treatment KPS score was increased in 15 patients, stable in 3 patients, and decreased in 1 patient; 1 patient died.
The treatment principle of inoperable or surgeryrefused patients with locally advanced pancreatic cancer is to control the local lesion, improve symptoms, improve quality of life, and prolong survival time. Although conventional radiotherapy can improve prognosis and increase patient爷s quality of life, the dose is difficult to be raised, because in the process of radiotherapy pancreatic tumor target has low conformal degree and is influenced by respiratory motion. However the emergence of CyberKnife gives a good solution to this problem. In this study, CyberKnife was used to treat 20 patients with locally advanced pancreatic cancer, with the isodose level of tumor target prescription dose reaching 75% to 85% . This treatment increased target conformal deg ree and at the same time made the surrounding normal tissues receiving a small dose of radiation. During the followup of 3 to 11 months, only some patients had mild weakness, nausea, vomiting, myelosuppression, and other treatmentrelated adverse reactions, which were relieved after active symptomatic treatment. The followup with regular examination of abdominal CT and related indicators showed that the local remission rate of pancreatic lesions reached 75% ; most of the patients with pain got good relief (relief rate was 86.7% ), and the tumor marker CA199 which was highly associated with pancreatic cancer and the obstructive jaundice index caused by pancreatic lesions were significantly reduced after CyberKnife treatment; at the same time the quality of life of patients was also improved, with KPS score significantly increased compared with that before treatment. These gratifying results are mainly due to many technical advantages of CyberKnife.
CyberKnife is a new stereotactic radiotherapy technique emerging in recent years. It uses lightweight linear accelerator giving 6 MV Xray with accuracy controlled below 0.5 mm, and can perform realtime position adjustment and verification (before and after treatment) for malignant tumors of the whole body. The treatment has high accuracy and improves the ability to protect sensitive tissue, and can track the tumor movement due to breathing to give irradiation, which overcomes the troubling tumor movement along with breathing. Therefore, it can better prevent the normal tissue surrounding tumor lesions from injury, give one or several times (typically 25 times) of large dose radiation to tumor lesions, shorten disease course, and improve the local control rate [810] . By observing the injury of normal tissues surrounding all lesions treated by CyberKnife, we found that, with high local control rate and fewer cases with radiation injury, the damage of adjacent normal tissues surrounding the lesions caused by CyberKnife is very small. Koong .
[11] conducted a phase I dose escalation study on CyberKnife for locally advanced pancreatic cancer, with 15 patients enrolled in the clinical study, and the results showed that a single dose of 25 Gy could obtain a local control rate of 10% and significantly reduce symptoms. After that he conducted another phase I clinical study in locally advanced pancreatic cancer [12] , in which 16 patients received 45 Gy of radiation for pancreatic lesions by intensity modulated radiation therapy and concurrent chemotherapy, and then received local boost of 25 Gy by CyberKnife in 1 month. All patients completed the treatment with a local control rate of 94% , but overall survival (OS) rate did not significantly increase. Moreover, Kim .
[13] performed a prospective study on locally advanced pancreatic cancer in 2006, and in one group 19 patients received CyberKnife treatment alone (339 Gy/3 fractions) and in the other group 21 patients received boost by CyberKnife (1319 Gy/1 fraction) after conventional external irradiation (40 Gy/20 fractions), among whom 2 patients received chemotherapy. The results showed that the median survival time (MST) and 1year OS were 10 months and 21.1% in the former group, and 13 months and 57.9% in the latter group, with no statistically significant difference ( = 0.086) between two groups but a trend of better prognosis in the latter group. In addition, there were significantly different acute radiation toxicities between two groups. In the present study, 20 patients with advanced pancreatic cancer received CyberKnife treatment alone and obtained a local control rate (CR + PR) of 75%; 15 patients with pain had a pain relief rate of close to 90% after treatment; and, of 13 patients with obstructive jaundice, 10 patients爷 symptoms were obviously relieved, with a remission rate of 76.9%. Compared with foreign data, we got similar local control rate and symptom improvement. However, in this study there was neither control group nor combination of conformal radiotherapy and chemotherapy, which would be included in our future research. We have confirmed that CyberKnife is a safe and effective new means that can improve the local control rate and relieve symptoms in patients with advanced pancreatic cancer. However, current samples are small, therefore the clinical study with larger sample, longterm efficacy and toxicity evaluation, and combined chemotherapy is needed.
The efficacy of conventional radiotherapy and threedimensional conformal radiotherapy in pancreatic cancer is difficult to be improved, which is mainly because realtime position tracking cannot be conducted during the treatment. The Synchrony technology of CyberKnife is one of the most mature realtime tracking technologies in clinical application, and relevant research results show that its accuracy is around 1.5 mm [14] . Therefore it can reduce the uncertainty of tumor location through respiration adaptive tracking system, and also reduce the increase of PTV caused by respiratory movement, thereby reduce target volume as possible, increase the dose effectively, reduce the toxicities of normal tissues, and also significantly improve the efficacy [1416] . Of 20 patients in this study, 5 received vertebral tracking (XSight) therapy and 15 received synchronous respiratory tracking technique (Synchrony) with gold seed fiducials implanted in tumors. During the completion process of plans, 80% of average isodose wrapped the target volume, with CI reaching 1.1 and nCI reaching 1.28. While improving the tumor dose, CyberKnife significantly reduced the dose to normal tissue. The results showed that CyberKnife needed only a short period, 1 to 6 days, in treating locally advanced pancreatic cancer, and the shortterm efficacy was good, with a total effective rate (CR + PR) of 75%. At the same time, being a new exploration in the treatment of locally advanced pancreatic cancer, it could relieve abdominal pain and jaundice symptoms in patients, significantly improve quality of life, and increase local control rate. The main side effects of CyberKnife are shortterm fatigue, nausea and vomiting, and mild hematologic toxicity, which can be relieved by active symptomatic treatment; and no greater than gradeIII radiation toxicity is observed. Longterm toxicity has not been reported in previously clinical followup studies, and it is worthy of further attention and followup.
In the present study, the selected patients are with locally advanced pancreatic cancer, with a certain limitation in the sample collection. At the same time, since CyberKnife is still a new technology, in some patients the dose per fraction is still low, and treatment modality and dose are still at exploratory stage. However, the preliminary results of CyberKnife for locally advanced pancreatic cancer show that this technology has significant shortterm efficacy in locally advanced pancreatic caner, and can effectively control the tumor, relieve or eliminate the clinical symptoms, and at the same time significantly reduce treatment course with mild acute toxicities and good tolerability. In the next step, we will further expand sample size, use comprehensive treatment modality, and conduct further observation on longterm efficacy, toxicities and survival rate.
